Treating acute myeloid leukemia (AML) depends on knowing what goes wrong inside cells. A new study suggests that two genetic ...
New research provides a mechanistic map of how genetic mutations disrupt RNA splicing in acute myeloid leukemia.
PRESS RELEASE AB SCIENCE REPORTS FOURTH CONSECUTIVE CASE OF RESPONSE FROM PHASE 1 DATA FOR THE COMBINATION OF AB8939 WITH VENETOCLAX FOR THE TREATMENT OF REFRACTORY OR RELAPSED ACUTE MYELOID LEUKEMIA ...
AZoLifeSciences on MSN
Dual genetic mutations drive RNA mis-splicing and leukemia progression
Treating acute myeloid leukemia (AML) depends on knowing what goes wrong inside cells. A new study suggests that two genetic ...
The illustration of protein structure (domains) on the left side, and corresponding exons in the FLT3 gene are displayed on the right side. FMS-like tyrosine kinase 3 (FLT3) mutations represent some ...
Acute myeloid leukemia (AML) can occur in both children and adults. However, the genetic drivers of disease can differ depending on the patient’s age and knowing this information may inform on ...
Preclinical AML studies showed palbociclib plus venetoclax produced stronger, more durable anti‑leukemia activity than venetoclax alone and may overcome resistance.
Compared with white patients, Black patients with acute myeloid leukemia (AML) were on average more than five years younger at diagnosis, more than 30% more likely to die of their disease, and more ...
Compared with white patients, Black patients with acute myeloid leukemia (AML) were on average more than five years younger at diagnosis, more than 30% more likely to die of their disease, and more ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback